# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Robert Burns maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price tar...
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming bina...
Truist Securities analyst Asthika Goonewardene maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $19 pric...
HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $24 price...
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of...